CD68 and nonpapillary renal cell carcinoma: To further test the possible synergistic effect of FCER1G and CD68 expression in predicting the prognosis of ccRCC, 321 patients in TMA-2020 were classified into four groups using the cut-off values determined from the ROC curve: FCER1Ghigh, CD68high; FCER1Ghigh, CD68low; FCER1Glow, CD68high and FCER1Glow, CD68low.